title: The effect of low-dose okt3 monoclonal-antibody therapy on k562 cytotoxicity in human cancer-patients.
abstract: Low concentrations of monoclonal antibodies (mAb) specific for the CD3 component of the T cell receptor complex (TcR) may be both immunosuppressive or potent activators of T cell function in vitro depending upon the experimental situation. The anti-CD3 mAb OKT3 is imnmunosuppressive at high doses (5 mg/day for 10 to 14 days) in transplant patients. We undertook a preliminary study to investigate the effect of a single intravenous injection of 50 mu g to 0.5 mu g of OKT3 mAb in cancer patients. OKT3 modulated cytotoxicity with minimal clinical toxicity at low doses and may be of use in cancer immunotherapy protocols.
authors.affiliation: UNIV LEICESTER,LEICESTER ROYAL INFIRM,SCH MED,DEPT SURG,LEICESTER LE2 7LX,ENGLAND.
authors.forename: J
authors.initials: J
authors.lastname: Hollingworth
authors.forename: R
authors.initials: R
authors.lastname: Catterick
authors.forename: T
authors.initials: T
authors.lastname: Horsburgh
authors.forename: P
authors.initials: P
authors.lastname: Veitch
authors.forename: P
authors.initials: P
authors.lastname: Bell